Belite Bio announced it will present topline results from its Phase 3 DRAGON study of tinlarebant, an oral therapy for Stargardt disease, at two upcoming medical conferences in July 2026. Tinlarebant aims to reduce toxic vitamin A by-products in the eye that cause retinal degeneration. The drug has received multiple regulatory designations and met its primary endpoint in the Phase 3 trial. Presentations will be held in Sydney and Montréal, highlighting progress in treating this currently untreatable inherited retinal disease. Further trials are ongoing for both Stargardt disease and related retinal conditions.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Industrial Development Funding (IDF) and Oaktree have committed $1.7 billion to support Bloom Energy's fuel cell technology for building AI cloud infrastructure for Nebius. This project will provide dedicated behind-the-meter power to meet the high c...
